Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2023 | MAIC of momelotinib versus fedratinib safety in myelofibrosis

Lucia Masarova • 9 Sep 2023
SOHO 2023
Myelofibrosis Myeloproliferative Neoplasms Fedratinib Momelotinib
JAKARTA-2 MOMENTUM SIMPLIFY-1 SIMPLIFY-2

Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares the findings of a matching-adjusted indirect comparison (MAIC) study which compared safety data for momelotinib and fedratinib in patients with myelofibrosis (MF). Following comparison of data from several studies, momelotinib displayed superiority for a range of adverse events (AEs). This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Lucia Masarova

1:19
What's on the horizon for the treatment of MPNs?
Lucia Masarova • 9 Dec 2023
2:13
Splicing mutations in post-ET/post-PV myelofibrosis
Lucia Masarova • 9 Dec 2023
3:17
Estimating transfusion-related medical costs & time burden in patients with MF in SIMPLIFY-1
Lucia Masarova • 9 Dec 2023
3:18
Cladribine-based chemotherapy for patients with secondary AML arising after MPNs
Lucia Masarova • 9 Dec 2023

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals